EPA-EE Nano-Lipid Emulsion for Oral Bioavailability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current EPA formulations have low bioavailability and poor absorption rates, leading to suboptimal lipid-lowering and atherosclerosis treatment effects due to rapid metabolism and inability to maintain effective drug concentrations in blood.

Innovation Solution

An EPA-EE nano-lipid composition is developed, comprising EPA-EE, a highly unsaturated phospholipid emulsifier, a stabilizer, and auxiliary materials, which is formulated into a submicron emulsion to enhance bioavailability and maintain effective blood concentrations.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If soft capsule formulations are used for EPA delivery, then the formulation is stable and easy to manufacture, but the bioavailability and absorption rate are poor (less than 20%)

Engineering Contradiction:

Improveformulation stabilityVSAvoidbioavailability

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent transforms EPA from traditional soft capsule form into a nano-lipid emulsion with particle size controlled at 50-200nm. This parameter change in particle size dramatically improves bioavailability while maintaining formulation stability through optimized emulsion composition including phospholipids and cholesterol.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite nano-lipid emulsion system combining EPA with phospholipids, cholesterol, and other auxiliary materials. This composite structure enhances both the stability of the formulation and the bioavailability of EPA, resolving the contradiction between stability and absorption rate.

Inventive Principle:

Principle #40Composite materials

2Ease of manufacture

If conventional EPA formulations are used, then the manufacturing process is simple, but the absorption rate is poor and drug concentration in blood cannot be maintained

Engineering Contradiction:

Improvemanufacturing simplicityVSAvoidduration of effective drug concentration

Core Design Contradiction:

Ease of manufactureVSDuration of action of moving object

Solution Approach 1:

The patent applies parameter changes by controlling the particle size of EPA nano-lipid emulsion within 50-200nm and optimizing the composition ratios of phospholipids (1-10%), cholesterol (0.1-5%), and auxiliary materials. These parameter optimizations extend the duration of effective drug concentration in blood while maintaining reasonable manufacturing complexity.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces phospholipids and cholesterol as intermediary substances that facilitate EPA absorption and prolong its presence in blood. These mediators form a stable nano-emulsion structure that enhances drug concentration duration without significantly complicating the manufacturing process.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Quantity of substance

If high-dose EPA is administered to overcome rapid metabolism, then the therapeutic effect may be improved, but toxic side effects on liver and kidneys increase

Engineering Contradiction:

ImproveEPA concentrationVSAvoidtoxic side effects

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent changes the physical state of EPA from bulk form to nano-scale emulsion (50-200nm), which dramatically improves absorption efficiency. This allows achieving therapeutic EPA concentrations with lower doses, thereby reducing toxic side effects on liver and kidneys while maintaining effective treatment levels.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces the conventional mechanical delivery system (soft capsules) with a nano-emulsion system that leverages surface science and colloid chemistry principles. This substitution enables more efficient EPA delivery and metabolism, reducing the need for high dosing and associated toxicity.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The EPA-EE nano-lipid composition significantly improves the oral absorption and bioavailability of EPA, maintaining effective blood concentrations for a longer period, thereby enhancing blood lipid-lowering and atherosclerosis treatment effects.

Implementation Method 1

Methodology Applied

Scientific EffectEmulsion: Emulsion

Data Source

PatentUS20250090547A1EPA-EE lipid nanocomposite, formulation thereof, preparation method therefor, and application thereof

Publication Date: 2025.03.20 SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES

AI summary

The present application relates to an EPA-EE nano-lipid composition and a formulation, a preparation method, and an application thereof. The EPA-EE nano-lipid composition includes a raw material having a high content of EPA-EE as a primary ingredient and includes an emulsifier containing a highly unsaturated phospholipid. The EPA-EE nano-lipid composition can be prepared into a sub-micron emulsion at nanoscale for use as an oral formulation.